Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP:AZNCF)

186.40 +3.40 (+1.86%)
Streaming Delayed Price Updated: 11:09 AM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Japan Approves AstraZeneca's Two Treatments For Asthma, Rare Form Of Cancer ↗
 
Via Benzinga
News headline image
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med ↗
 
Via Benzinga
News headline image
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma ↗
 
Via Benzinga
News headline image
AstraZeneca's Asthma Treatment Scores European Approval ↗
 
Via Benzinga
News headline image
AstraZeneca's COVID-19 Antibody Treatment Scores Approval In Europe ↗
 
Via Benzinga
News headline image
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing ↗
 
Via Benzinga
News headline image
AstraZeneca's Blood Clot Treatment Hits Primary Goal In Rare Blood Disorder Trial ↗
 
Via Benzinga
News headline image
Top Financial Stories Tuesday, September 13: Elon Musk's Takeover Set To Get Twitter Shareholder Approval, Intel Slashes Mobileye IPO Valuation, Goldman Sachs To Layoff About 500 Jobs And More... ↗
Wall Street Journal 
Via Benzinga
News headline image
US Judge Dismisses Shareholder Lawsuit Over AstraZeneca's COVID-19 Vaccine Disclosures: Report ↗
 
Via Benzinga
News headline image
AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer ↗
 
Via Benzinga
News headline image
AstraZeneca Imfinzi Combo Scores FDA Approval As First Immunotherapy Regimen For Biliary Tract Cancer ↗
 
Via Benzinga
News headline image
AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment ↗
 
Via Benzinga
News headline image
Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial ↗
 
Via Benzinga
News headline image
AstraZeneca Touts Positive Farxiga Data, Seeks Label Expansion In Heart Failure ↗
AstraZeneca Plc (NASDAQ: AZN) laid out the details of the Farxiga's performance in another heart failure patient population at the European Society of Cardiology Congress. 
Via Benzinga
News headline image
Back-To-Back Three Japanese Approvals For AstraZeneca's Rare Disease Treatments ↗
 
Via Benzinga
News headline image
AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions ↗
In a Reuters report, AstraZeneca Plc's (NASDAQ: 
Via Benzinga
News headline image
AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report ↗
 
Via Benzinga
News headline image
UK Government Will Not Buy More AstraZeneca's COVID-19 Treatment ↗
 
Via Benzinga
News headline image
AstraZeneca-Merck's Prostate Cancer Drug Under FDA Priority Review For Expanded Use ↗
 
Via Benzinga
News headline image
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study ↗
 
Via Benzinga
News headline image
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation ↗
 
Via Benzinga
News headline image
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients ↗
 
Via Benzinga
News headline image
AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting ↗
 
Via Benzinga
News headline image
Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs ↗
 
Via Benzinga
News headline image
AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer ↗
 
Via Benzinga
News headline image
AstraZeneca Drops Moderna-Partnered, Phase 2 Heart Disease Drug Candidate ↗
AstraZeneca Plc (NASDAQ: AZN) has removed a Moderna Inc (NASDAQ: MRNA)-partnered cardiovascular disease candidate from its phase 2 pipeline.  
Via Benzinga
News headline image
AstraZeneca Q2 Highlights: Profits Fall, COVID-19 Vaccine Sales Dip, Lifts Annual Sales Guidance ↗
 
Via Benzinga
News headline image
Europe's CHMP Recommends Approving AstraZeneca's Asthma, Neuromuscular Disorder Treatments ↗
 
Via Benzinga
News headline image
Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.